Search Results - "Moshayedi, Natalie"

Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma by Gong, Jun, Thomassian, Shant, Kim, Sungjin, Gresham, Gillian, Moshayedi, Natalie, Ye, Jason Y., Yang, Julianne C., Jacobs, Jonathan P., Lo, Simon, Nissen, Nick, Gaddam, Srinivas, Tighiouart, Mourad, Osipov, Arsen, Hendifar, Andrew

“…In this phase I dose-escalation trial, we assess the maximum tolerated dose (MTD) of Bermekimab in combination with Nanoliposomal Irinotecan (Nal-Iri) and…”
Get full text

Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5‑fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma by Gong, Jun, Thomassian, Shant, Kim, Sungjin, Gresham, Gillian, Moshayedi, Natalie, Ye, Jason Y., Yang, Julianne C., Jacobs, Jonathan P., Lo, Simon, Nissen, Nick, Gaddam, Srinivas, Tighiouart, Mourad, Osipov, Arsen, Hendifar, Andrew

Get full text

Primary survival outcomes between metastatic sites in ovarian cancer by Moshayedi, Natalie, Hill, Torrey, Heimer, Ingrid, Speckart, Jessica, Rahnemai-Azar, Amir

Get full text

Race, sex, age, and geographic disparities in pancreatic cancer incidence by Moshayedi, Natalie, Escobedo, Anna Loraine, Thomassian, Shant, Osipov, Arsen, Hendifar, Andrew Eugene

“…Abstract only 520 Background: Pancreatic cancer has a poor prognosis and a 5-year survival rate of 10%. A population-risk level analysis of pancreatic cancer…”
Get full text

Retrospective study of survival outcomes in patients with hereditary pathogenic and variants of unknown significance mutations in pancreatic adenocarcinoma by Lin, Ching Ying, Moshayedi, Natalie, Thomassian, Shant, Gong, Jun, Osipov, Arsen, Hendifar, Andrew Eugene

“…Abstract only 616 Background: Since 2019, all patients with pancreatic adenocarcinoma (PDAC) are recommended to undergo germline testing per the National…”
Get full text

A phase I study of first-line L-glutamine (Gln) with gemcitabine (gem) and nab-paclitaxel (nab-p) in advanced pancreatic cancer (GlutaPanc) by Davelaar, John, Tighiouart, Mourad, Hendifar, Andrew Eugene, Osipov, Arsen, Moshayedi, Natalie, Placencio-Hickok, Veronica, Bhowmick, Neil, Gong, Jun

“…Abstract only TPS636 Background: Cytotoxic chemotherapy remains the preferred first-line treatment for advanced or unresectable pancreatic cancer with…”
Get full text

Fecal microbiome composition in pancreatic cancer cachexia and response to nutrition support by Moshayedi, Natalie, Yang, Julianne, Lagishetty, Venu, Jacobs, Jonathan, Placencio-Hickok, Veronica, Osipov, Arsen, Hendifar, Andrew Eugene, Gong, Jun

“…Abstract only 4129 Background: Pancreatic ductal adenocarcinoma (PDAC) carries a poor prognosis with a 5-year survival rate of 10.0%. Previous studies in stool…”
Get full text

Metabolomics in advanced pancreatic cancer (PC) patients (pts) achieving weight stability on enteral feeding for cachexia by Akinsola, Rasaq, Muranaka, Hayato, Hendifar, Andrew Eugene, Osipov, Arsen, Moshayedi, Natalie, Thomassian, Shant, Stotland, Aleksandr, Parker, Sarah, Van Eyk, Jennifer, Devkota, Suzanne, Bhowmick, Neil, Gong, Jun

“…e16291 Background: We previously showed that enteral feeding was associated with weight stability and compositional changes in the gut microbiome with…”
Get full text

Plasma metabolomics to predict chemotherapy (CTX) response in advanced pancreatic cancer (PC) patients (pts) on enteral feeding for cachexia by Muranaka, Hayato, Moshayedi, Natalie, Hendifar, Andrew Eugene, Osipov, Arsen, Placencio-Hickok, Veronica, Stotland, Aleksandr, Parker, Sarah, Van Eyk, Jennifer, Bhowmick, Neil, Gong, Jun

“…Abstract only 600 Background: We evaluated the potential of plasma metabolites as predictors of response to CTX in a prospective cohort of pts who received…”
Get full text

Hyaluronan heterogeneity in pancreatic ductal adenocarcinoma, primary tumors, and sites of metastasis by Placencio-Hickok, Veronica, Lauzon, Marie, Moshayedi, Natalie, Guan, Michelle, Kim, Sungjin, Pandol, Stephen Jacob, Larson, Brent K, Gong, Jun, Hendifar, Andrew Eugene, Osipov, Arsen

“…Abstract only e16231 Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers with an estimated five-year survival rate of…”
Get full text

Exceptional Response to Erdafitinib in FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma by Ng, Camille F, Glaspy, John, Placencio-Hickok, Veronica R, Thomassian, Shant, Gong, Jun, Osipov, Arsen, Hendifar, Andrew E, Moshayedi, Natalie

“…Despite advances in cancer therapeutics, pancreatic ductal adenocarcinoma (PDAC) remains among the deadliest malignancies, with a poor prognosis at time of…”
Get more information

Impact of site-specific metastases on survival outcomes in pancreatic adenocarcinoma (PDAC) patients: A national analysis by Nikravesh, Nima, Gresham, Gillian, Anderson, Eric, Elmadbouh, Omer, Thomassian, Shant, Moshayedi, Natalie, Davelaar, John, Lo, Simon, Gaddam, Srinivas, Nissen, Nicholas, Kosari, Kambiz, Gangi, Alexandra, Pandol, Stephen Jacob, Gong, Jun, Hendifar, Andrew Eugene, Osipov, Arsen

“…e16270 Background: PDAC is the third most fatal cancer, where most patients present with metastases at diagnosis. Previous studies, including a retrospective…”
Get full text

Genomic correlates of response to capecitabine and temozolomide (CAPTEM) in pancreatic neuroendocrine tumors by Lee, Patrick, Blais, Edik Matthew, Gong, Jun, Osipov, Arsen, Moshayedi, Natalie, Thomassian, Shant, Ng, Camille, Chuy, Jennifer W., Matrisian, Lynn McCormick, Petricoin, Emanuel, Pishvaian, Michael J., Hendifar, Andrew Eugene

“…4124 Background: Despite the frequent use of capecitabine and temozolomide (CAPTEM) to treat metastatic, well-differentiated pancreatic neuroendocrine tumors…”
Get full text

Mo1144 DECREASED EXPRESSION OF HISTONE DEACETYLASE 4 (HDAC4) AND YES-ASSOCIATED PROTEIN 1 (YAP) IN IMMUNOSUPPRESSIVE MYELOID CELLS AND FIBROBLASTS IN THE TME OF PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) IS ASSOCIATED WITH EXCEPTIONAL CLINICAL RESPONSE by Elmadbouh, Omer H., Davelaar, John, Lim, Adrian, Abbas, Anser A., Minasyan, Angela, Zhou, Wei, Ou, Yan, Moshayedi, Natalie, Larson, Brent K., Nissen, Nicholas N., Lo, Simon K., Gaddam, Sri, Kosari, Kambiz, Gong, Jun, Hendifar, Andrew, Pandol, Stephen J., Edderkaoui, Mouad, Wang, Qiang, Osipov, Arsen

Get full text

Real-world clinical outcomes and molecular features of lung-specific and liver-specific metastases in pancreatic ductal adenocarcinoma (PDAC) by Osipov, Arsen, Blais, Edik Matthew, Davelaar, John, Moshayedi, Natalie, Nikravesh, Nima, Gresham, Gillian, Zheng, Lei, McRee, Autumn Jackson, Chuy, Jennifer W., Shroff, Rachna T., Wadlow, Raymond Couric, Gregory, Gary Lee, DeArbeloa, Patricia, Matrisian, Lynn McCormick, Petricoin, Emanuel, Pishvaian, Michael J., Thomassian, Shant, Gong, Jun, Hendifar, Andrew Eugene

“…Abstract only 532 Background: PDAC remains one of the most lethal malignancies following metastatic presentation, typically to the liver or lung. Previous…”
Get full text

Hyaluronan heterogeneity in pancreatic ductal adenocarcinoma: Primary tumors compared to sites of metastasis by Placencio-Hickok, Veronica R., Lauzon, Marie, Moshayedi, Natalie, Guan, Michelle, Kim, Sungjin, Nissen, Nicholas, Lo, Simon, Pandol, Stephen, Larson, Brent K., Gong, Jun, Hendifar, Andrew E., Osipov, Arsen

“…Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers with poor survival. The dense desmoplastic stroma in PDAC contributes to…”
Get full text

Plasma Metabolomics Predicts Chemotherapy Response in Advanced Pancreatic Cancer by Muranaka, Hayato, Hendifar, Andrew, Osipov, Arsen, Moshayedi, Natalie, Placencio-Hickok, Veronica, Tatonetti, Nicholas, Stotland, Aleksandr, Parker, Sarah, Van Eyk, Jennifer, Pandol, Stephen J, Bhowmick, Neil A, Gong, Jun

“…Pancreatic cancer (PC) is one of the deadliest cancers. Developing biomarkers for chemotherapeutic response prediction is crucial for improving the dismal…”
Get full text

Tumor hyaluronan as a novel biomarker in non-small cell lung cancer: A retrospective study by Gong, Jun, Guan, Michelle, Kim, Haesoo, Moshayedi, Natalie, Mehta, Sejal, Cook-Wiens, Galen, Larson, Brent K, Zhou, Jenny, Patel, Rishi, Lapite, Isaac, Placencio-Hickok, Veronica R, Tuli, Richard, Natale, Ronald B, Hendifar, Andrew E

“…Hyaluronan (HA) accumulation is associated with tumorigenesis and aggressive tumor behavior. We investigated the biomarker potential of HA in non-small cell…”
Get full text

Gut microbiome and pancreatic cancer cachexia: An evolving relationship by Hendifar, Andrew, Akinsola, Rasaq, Muranaka, Hayato, Osipov, Arsen, Thomassian, Shant, Moshayedi, Natalie, Yang, Julianne, Jacobs, Jonathan, Devkota, Suzanne, Bhowmick, Neil, Gong, Jun

“…Nearly 80% of patients with pancreatic ductal adenocarcinoma (PDAC) develop cachexia along their disease course. Cachexia is characterized by progressive…”
Get full text

A Comparison of Clinicopathologic Outcomes Across Neoadjuvant and Adjuvant Treatment Modalities in Resectable Gastric Cancer by Anderson, Eric, LeVee, Alexis, Kim, Sungjin, Atkins, Katelyn, Guan, Michelle, Placencio-Hickok, Veronica, Moshayedi, Natalie, Hendifar, Andrew, Osipov, Arsen, Gangi, Alexandra, Burch, Miguel, Waters, Kevin, Cho, May, Klempner, Samuel, Chao, Joseph, Kamrava, Mitchell, Gong, Jun

“…Treatment of resectable gastric cancer (RGC) uses a multimodal approach, including surgical treatment and chemotherapy with or without radiation therapy, and…”
Get full text